Added to YB: 2025-08-12
Pitch date: 2025-08-08
MRNA [neutral]
Moderna, Inc.
+409.79%
current return
Author Info
No bio for this author
Upgrade to Yellowbrick Premium to unlock investor returns. Upgrade to Yellowbrick Premium
Company Info
Moderna, Inc., a biotechnology company, provides messenger RNA medicines in the United States, Europe, and internationally.
Market Cap
$25.3B
Pitch Price
$26.15
Price Target
N/A
Dividend
N/A
EV/EBITDA
-9.33
P/E
-7.91
EV/Sales
8.82
Sector
Biotechnology
Category
turnaround
Show full summary:
Natan's Notes #9: Q2 Updates on $MRNA
MRNA (earnings update - hold): Moderna cutting $400M costs in 2025 with 800+ layoffs; 2025 sales guidance trimmed to $2.2B on UK shipment delay to Q1 2026. Pipeline progress: positive Phase 3 flu results support 2026 approval, CMV data coming fall, norovirus pending. Still compelling risk/reward despite poor stock performance.
Read full article (2 min)